MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

PTC Therapeutics Inc

Cerrado

SectorSalud

48.23 3.63

Resumen

Variación precio

24h

Actual

Mínimo

45.44

Máximo

48.7

Métricas clave

By Trading Economics

Ingresos

41M

-66M

Ventas

16M

213M

BPA

-0.342

Margen de beneficio

-30.907

Empleados

939

EBITDA

3M

-47M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+42.92% upside

Dividendos

By Dow Jones

Próximas Ganancias

24 abr 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

765M

4.3B

Apertura anterior

44.6

Cierre anterior

48.23

Noticias sobre sentimiento de mercado

By Acuity

31%

69%

96 / 386 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

PTC Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

2 dic 2024, 12:47 UTC

Principales Movimientos del Mercado

PTC Therapeutics Shares Jump on Pact With Novartis

Comparación entre iguales

Cambio de precio

PTC Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

42.92% repunte

Estimación a 12 meses

Media 66.6 USD  42.92%

Máximo 113 USD

Mínimo 50 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para PTC Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

12 ratings

6

Comprar

5

Mantener

1

Vender

Puntuación técnica

By Trading Central

45.4 / 56.23Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Weak Bearish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

96 / 386 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de PTC Therapeutics Inc

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.